Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher

Showing results (701-710 of 6,834) with videos related to

Pageof 684
Sort By:
Nature|June 9, 2021
Landmark Alzheimer's drug approval confounds research communityAsher Mullard
Nature Reviews. Drug Discovery|May 10, 2022
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billionAsher Mullard
Nature Reviews. Drug Discovery|May 10, 2022
FDA approves first cardiac myosin inhibitorAsher Mullard
Nature Reviews. Drug Discovery|June 17, 2022
From pandemic preparedness to public-private partnershipsAsher Mullard
Nature Reviews. Drug Discovery|December 5, 2020
COVID-19 vaccines buoy hopeAsher Mullard
Nature Reviews. Drug Discovery|July 15, 2021
Can a platform of platform companies open up more opportunities?Asher Mullard
Nature Reviews. Drug Discovery|July 9, 2021
Alzheimer antibody rush begins, as efficacy concerns remainAsher Mullard
Nature Reviews. Drug Discovery|July 5, 2024
FDA approves third anti-amyloid antibody for Alzheimer diseaseAsher Mullard
Nature Reviews. Drug Discovery|May 20, 2024
RNA-rewriting candidate moves into the clinicAsher Mullard
Nature Reviews. Drug Discovery|June 27, 2025
FDA approves first factor XIIa inhibitor, for hereditary angioedemaAsher Mullard
Pageof 684

Showing results (701-710 of 6,834) with videos related to

Sort By:
Pageof 684
Nature|June 9, 2021
Landmark Alzheimer's drug approval confounds research communityAsher Mullard
Nature Reviews. Drug Discovery|May 10, 2022
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billionAsher Mullard
Nature Reviews. Drug Discovery|May 10, 2022
FDA approves first cardiac myosin inhibitorAsher Mullard
Nature Reviews. Drug Discovery|June 17, 2022
From pandemic preparedness to public-private partnershipsAsher Mullard
Nature Reviews. Drug Discovery|December 5, 2020
COVID-19 vaccines buoy hopeAsher Mullard
Nature Reviews. Drug Discovery|July 15, 2021
Can a platform of platform companies open up more opportunities?Asher Mullard
Nature Reviews. Drug Discovery|July 9, 2021
Alzheimer antibody rush begins, as efficacy concerns remainAsher Mullard
Nature Reviews. Drug Discovery|July 5, 2024
FDA approves third anti-amyloid antibody for Alzheimer diseaseAsher Mullard
Nature Reviews. Drug Discovery|May 20, 2024
RNA-rewriting candidate moves into the clinicAsher Mullard
Nature Reviews. Drug Discovery|June 27, 2025
FDA approves first factor XIIa inhibitor, for hereditary angioedemaAsher Mullard
Pageof 684